FDA Determines Regulatory Review Period for REYATAZ Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of REYATAZ, a human drug product, in accordance with federal regulations and following a submission to the Director of Patents and Trademarks at the US Department of Commerce.